News

Boston Scientific, a developer and marketer of medical devices, has reported a net loss of $13m, or $0.01 per diluted share, for the first quarter of 2009, compared

In this role, Mr Schaeffler will lead the organization’s public policy efforts in Washington, DC and report to DaVita CEO Kent Thiry. Prior to joining DaVita, Mr Schaeffler

The diagnostic test is based on technology being developed by Antigen Express. The technology being developed at Antigen Express allows for more potent and specific activation of immune

According to Wound Management Technologies, CellerateRx is FDA cleared as a medical device and is indicated for all acute and chronic wounds except for third degree burns. Cathy

Affinity Capital Management led the round with Johnson & Johnson Development, L Capital Partners, and Clarian Health Ventures participating as first time investors. Existing investors, Prism VentureWorks, Three

Microline Pentax, a wholly owned subsidiary of Hoya and a manufacturer of reposable instruments for minimally invasive surgery, has acquired Starion Instruments, a developer of surgical technology for

The lawsuit contends that Davol’s recently released Sorbafix device infringes multiple claims of Covidien’s US patent. The patent generally relates to a system for controllably discharging fasteners from

These findings provide further evidence of mTOR as a validated cancer target with potential clinical applicability in several different tumor types, said Ariad. Deforolimus demonstrated potent single-agent, antitumor

The studies presented by the company further explore the detailed mechanism of action of LOR-253. The key findings include MTF-1 dependent induction of a novel tumor suppressor, namely